Atreca has announced it has secured $56 million in series A funding.

Atreca, based in Redwood City, California, is a privately held biotechnology company developing therapeutics drawn from human immune responses, including anti-cancer immune responses.

The funding round was led by an unidentified “large, U.S.-based, healthcare-focused fund.” Additional investors included the Bill & Melinda Gates Foundation, Mission Bay Capital and GlaxoSmithKline.

Atreca indicated it will use the financing to further development and advancement of the company’s product pipeline.